CRGX Penghasilan resik perusahaan cargo-tx.com

CARGO Therapeutics (CRGX) relies on scientific authority in the development of CAR-T systems. Flawless cryo-logistics guarantee the viability of their products. Breakthrough clinical successes have secured maximum trust among oncologists for the brand, as evidenced by the company's profit margins. This chart visualizes financial stability, while -0.22 shapes the current metric, capturing the final operational result.

CRGX CARGO Therapeutics, Inc.: Penghasilan resik ing interval 21.02.2024 - 30.08.2025

Rincian metrik keuangan lan pasar CARGO Therapeutics, Inc. (CRGX)

- rega saham lan konsensus proyeksi valuasi:

Bagan rega CARGO Therapeutics, Inc|CRGX - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar CARGO Therapeutics, Inc|CRGX - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Siji Saham CARGO Therapeutics|CRGX - Aset Bersih Perusahaan|Koefisien Nilai Pasar marang Nilai Buku cargo-tx.com|CRGX - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi CARGO Therapeutics|CRGX - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas CARGO Therapeutics Inc.|CRGX - Gunggung utang perusahaan|Utang-utang marang nilai buku CARGO Therapeutics, Inc|CRGX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan CARGO Therapeutics|Likuiditas cepet cargo-tx.com

- data bathi bisnis lan rasio investasi:

CRGX - Penghasilan resik

Pambiji fundamental:CRGX CARGO Therapeutics, Inc

Produk sing diprodhuksi Cargo Therapeutics

High confidence among onco-hematologists in the innovative CAR-T therapies of CARGO Therapeutics (CRGX) creates a foundation for future capitalization, although the current stage of development makes this metric critically important. This indicator measures the difference between operating revenues and all expenses, separating real cash flow from speculative optimism, which allows for the diagnosis of the business's financial stability through the company's aggregate net income.

Pesaing utama